Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Website URL
Similar Companies999
Atreca
Atreca is a biotechnology company that develops novel therapeutics based on a deep understanding of the human immune response.
Sector
Subsector
Keywords
Location
total rounds
total raised
Aditxt Therapeutics
Aditxt, Inc. develops technologies to improve the health of the immune system through reprogramming and monitoring.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
AvidBiotics
AvidBiotics is a biotherapeutics company that develops novel proteins to target bacteria, virus-infected cells, and cancers.
Sector
Subsector
Keywords
Location
total rounds
total raised
Madam Therapeutics
Madam Therapeutics develops next-generation antibiotics for multi-drug resistant infections.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds8
Number of Funding Rounds
Money Raised
Their latest funding was raised on 03.10.2023. Their latest investor Biomedical Advanced Research and Development Authority (BARDA). Their latest round Grant
Biomedical Advanced Research and Development Authority (BARDA)
BARDA develops and purchases vaccines, drugs, therapies, and diagnostic tools for emergencies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation is a philanthropic organization.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors8
Number of lead investors
Number of investors
Biomedical Advanced Research and Development Authority (BARDA)
BARDA develops and purchases vaccines, drugs, therapies, and diagnostic tools for emergencies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Cowen Investment Management
Sustainable Private Equity and Credit Investments is a company focused on environmentally-friendly investments in private equity and credit.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Bill & Melinda Gates Foundation
The Bill & Melinda Gates Foundation is a philanthropic organization.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Acquisitions3
Agenovir Corporation acquired by Vir Biotechnology
acquirer
date
type
Agenovir Corporation
Agenovir is a company developing innovative antiviral therapeutics for diseases linked to viral reservoirs.
Sector
Subsector
Location
total rounds
total raised
Humabs acquired by Vir Biotechnology
acquirer
date
type
Humabs
Humabs is a Swiss company that develops human monoclonal antibodies to treat viral and bacterial infections.
Sector
Subsector
Keywords
Location
TomegaVax acquired by Vir Biotechnology
acquirer
date
type
TomegaVax
TomegaVax is developing cures for AIDS, malaria, tuberculosis, herpes, papillomavirus and hepatitis.
Sector
Subsector
Location
People
Founders2
Vicki Sato
Vicki L. Sato, Ph.D., serves as chairman of the board of directors at Vir. Dr. Sato is also a professor of management practice at Harvard Business School, and an affiliate member of the Department of Molecular and Cell Biology, Harvard University. She has taught in HBS Executive Education programs and is a business advisor to enterprises in the biotechnology and pharmaceutical industries. Dr. Sato retired in 2005 from Vertex Pharmaceuticals, where she served as president since 2000, with responsibility for research and development, business and corporate development, commercial operations, legal, and finance. Prior to becoming president, she was chief scientific officer, senior vice president of research and development, and chair of the Scientific Advisory Board. Under her leadership, Vertex created a diversified pipeline of drugs. Before joining Vertex, Dr. Sato was vice president of research at Biogen, Inc., where she led research programs in the areas of inflammation, thrombosis, and HIV disease, and she participated in the executive management of the company. Several molecules from those programs have now reached the marketplace. She also served as a member of the Biogen Scientific Board. Currently, Dr. Sato is a member of the board of directors of publicly held companies Bristol Myers Squibb Company, PerkinElmer Corporation, Borg Warner Corporation, and Syros Pharmaceuticals. She also serves as chair of the board of directors for Denali. Previously, Dr. Sato has served as an overseer of the Isabella Stewart Gardner Museum. She received her A.B. from Radcliffe College, and her A.M. and Ph.D. degrees from Harvard University. Following postdoctoral work at both the University of California Berkeley and Stanford Medical Center, Dr. Sato was appointed to the faculty of Harvard University, where she was an assistant and associate professor of biology.
current job
Vicki Sato
Robert Nelsen
Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including nineteen which have reached valuations exceeding $1 billion. His seed and early-stage investments include Illumina (ILMN); Alnylam Pharmaceuticals (ALNY); Juno Therapeutics (JUNO); Unity Biotechnology (UBX); Sienna Biopharmaceuticals (SNNA); Vir Biotechnology, Agios Pharmaceuticals (AGIO); Sage Therapeutics (SAGE); GRAIL, Ikaria; Kythera Biopharmaceuticals (KYTH), Receptos (RCPT); Aviron (AVIR); Denali Therapeutics (DNLI); Rubius Therapeutics, KSQ Therapeutics, Beam Therapeutics, NetBot; Bluebird Bio (BLUE); R2 Technology; XenoPort (XNPT); Caliper Life Sciences (CALP); Trubion Pharmaceuticals (TRBN); Adolor (ADLR); deCODE Genetics; Array BioPharma (ARRY); Editas (EDIT), IDUN Pharmaceuticals; Classmates.com; Hua Medicine; Fate Therapeutics (FATE); WuxiNextCODE; and Everyday Learning Corporation. Mr. Nelsen is a director of Vir Bio, GRAIL, Sienna Biopharmaceuticals, Beam Therapeutics, Unity Biotechnology, Denali Therapeutics, Arivale, Syros Pharmaceuticals, and serves as Chairman of Hua Medicine, among others. He previously served as a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology, and was a director of the National Venture Capital Association. Mr. Nelsen holds an M.B.A. from the University of Chicago and a B.S. from the University of Puget Sound with majors in Economics and Biology.
current job
count Of Investments
Robert Nelsen
Employee Profiles46
Johanna Friedl-Naderer
EVP & Chief Business Officer, Global
Herbert Skip Virgin
chief medical officer and head of the Altos Institute of Medicine
Heather Kelly
Director, research program management
Aswin Sundaram
Associate director, external manufacturing
Activity
Recent News27
The graph reveals the ratio (%) of positive news articles in a chosen time range